Report: FDA should implement life-cycle approach to oversee drugs

The FDA should oversee approved drugs on an ongoing basis to address post-market issues that will affect a medication's benefit-risk profile, according to a report issued by the Institute of Medicine. The IOM committee also said that health IT and analytics advances "likely will mean that observational approaches using large data sets will become more important over time."

View Full Article in:

IOM urges life-cycle approach' on drug monitoring - Modern Healthcare (subscription required) · U.S. needs better way to track drug safety - study - Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI